What does this research mean for the field?

Oral iron therapy is preferred for quiescent inflammatory bowel disease with mild iron deficiency, while intravenous iron supplementation is the therapy of choice for patients with active flares, severe anemia, or intolerance to oral preparations. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

Synthesize evidence from prospective trials evaluating oral versus intravenous iron replacement strategies for iron-deficiency anemia across different stages of inflammatory bowel disease.

April 23, 2023World Journal of Clinical CasesOpen Access

Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study

View Full Paper

Ask AI

Bookmark

Authors

NSNatália Souza Nunes Siqueira LPLívia Bitencourt Pascoal BRBruno Lima Rodrigues

Discussion

Member takes

Overview

Systematic review demonstrates the efficacy and safety of intravenous iron over oral supplements in active inflammatory bowel disease, indicating preferred routes depend on flare status.

Key Points

Synthesize evidence from prospective trials evaluating oral versus intravenous iron replacement strategies for iron-deficiency anemia across different stages of inflammatory bowel disease.
Conducted a systematic search of prospective trials published since 2004 across PubMed, EMBASE, the Cochrane Library, and regulatory databases (WHO, FDA, EMA).
Screened 632 identified articles and included 13 unique prospective publications encompassing 2,906 patients.
Oral iron therapy effectively replenished iron stores and restored hemoglobin levels primarily in quiescent disease stages, but faced limitations from poor tolerance and reduced intestinal absorption during inflammation.
Intravenous iron therapy demonstrated reliable efficacy during active disease flares without worsening inflammatory bowel disease activity and proved safe for concurrent administration with biologics.

Cite This Study

Siqueira et al. (2023) studied this question.

synapsesocial.com/papers/6aa920e023db11feac878239 https://doi.org/10.12998/wjcc.v11.i12.2740

View Full Paper

Ask AI

Bookmark

April 23, 2023World Journal of Clinical CasesOpen Access

Ferric carboxymaltose for anemia in Crohn’s disease patients at a tertiary center: A retrospective observational cohort study

View Full Paper

Ask AI

Bookmark

Authors

NSNatália Souza Nunes Siqueira LPLívia Bitencourt Pascoal BRBruno Lima Rodrigues

Discussion

Member takes

Overview

Systematic review demonstrates the efficacy and safety of intravenous iron over oral supplements in active inflammatory bowel disease, indicating preferred routes depend on flare status.

Key Points

Synthesize evidence from prospective trials evaluating oral versus intravenous iron replacement strategies for iron-deficiency anemia across different stages of inflammatory bowel disease.
Conducted a systematic search of prospective trials published since 2004 across PubMed, EMBASE, the Cochrane Library, and regulatory databases (WHO, FDA, EMA).
Screened 632 identified articles and included 13 unique prospective publications encompassing 2,906 patients.
Oral iron therapy effectively replenished iron stores and restored hemoglobin levels primarily in quiescent disease stages, but faced limitations from poor tolerance and reduced intestinal absorption during inflammation.
Intravenous iron therapy demonstrated reliable efficacy during active disease flares without worsening inflammatory bowel disease activity and proved safe for concurrent administration with biologics.

Cite This Study

Siqueira et al. (2023) studied this question.

synapsesocial.com/papers/6aa920e023db11feac878239 https://doi.org/10.12998/wjcc.v11.i12.2740

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark